Abstract

Lipid nanoparticles (LNPs) have emerged as effective delivery systems for nucleic acid therapies, exemplified by the success of Moderna and Pfizer/BioNTech COVID-19 vaccines. However, these therapies still present significant shelf-life stability limitations, often requiring conservative cold chain storage conditions. Given the hurdles associated with cold chain sup-ply, it is critical to overcome the stability challenges of these therapies. Drying technologies, such as spray drying (SD), can improve stability by removing water and preventing RNA hydrolysis and degradation. Nonetheless, shear and thermal stresses from SD can introduce additional risks to both the nucleic acid and the delivery system. Here, microfluidics was used to produce ribonucleic acid (RNA)-loaded LNPs with high encapsulation efficiency (> 95%), which were subsequently used to optimize the SD. A thorough process and formulation optimization was performed to maintain the LNPs’ colloidal stability and nucleic acid encapsulation efficiency after spray drying. Poloxamer 188 (P188) proved crucial in protecting LNPs from shear stress possibly due to its ability to insert itself within lipid layers, allowing the maintenance of colloidal stability during SD. Additionally, SD was benchmarked against freeze drying (FD) as an alternative low shear drying technology. Overall, the study demonstrates the importance of optimizing the SD process to enhance nucleic acid-loaded LNPs' stability and delivery potential.

Read the full article here